NEOG

LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company's possible violations of the federal securities laws.

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

BENSALEM, Pa. , Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.

Here, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.

I believe Neogen's recurring food safety products provide a foundation for its operating recovery. However, management has to execute carefully and proceed with the Petrifilm transition, which, if successful, should improve its cash flows long-term. Also, NEOG's recent genomics sale should give it extra flexibility, but we have to wait and see until we know how much its earnings may decrease as a result.

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Neogen NASDAQ: NEOG outlined a multi-year strategy at its first Investor Day, emphasizing a shift from business stabilization toward accelerated growth, higher margins and stronger cash generation. Management said the company has delivered positive core growth for four consecutive quarters and is targeting high-single-digit to low-double-digit long-term revenue growth, adjusted gross margins in the high-50% range, adjusted EBITDA margins of approximately 30% and free-cash-flow conversion of about 80% by fiscal 2031.

Neogen shares fell 7.22% after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination and at least 20 horse deaths. NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Neogen (NASDAQ: NEOG) shares fell over 7% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths.

Although the revenue and EPS for Neogen (NEOG) give a sense of how its business performed in the quarter ended August 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Neogen Corporation (NEOG) Q1 2027 Earnings Call Transcript